British Association of Dermatologists’ Biologic Interventions Registry (BADBIR)
Publications and authorship policy

The principles for publication and authorship as set out below fulfil the following requirements:

1. the need to recognise the contribution of many individuals and groups who have contributed to the implementation of BADBIR projects. This includes (broadly) the conception and design of the project, acquisition of the patient data (and all that that involves), analysis /interpretation of data and manuscript writing.
2. the need to comply with the statutory requirements as set out in the agreements between the BAD and sponsoring pharmaceutical companies
3. the need to avoid undue delays in publication and dissemination of prominent findings, in the interests of maximising impact upon human health, maintaining priority of publication (and protection of intellectual property)
4. adherence to Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Authorship and Contributorship (http://www.icmje.org)

The Research Group, answerable to the BADBIR Steering Committee, will be responsible for managing adherence to this policy.

Authorship

1. All PIs, and any site specific personnel who have, in the view of the local PI, made important substantial contributions to recruitment, will be listed in the acknowledgements section of all publications in order to recognise their important contribution made to BADBIR.

2. To qualify for authorship the individual must:
   - have made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data
   - have been involved in drafting the article or revising it critically for important intellectual content
   - have final approval of the version to be published and
   - be accountable for the manuscript

3. Requirements for authors and the level of input to manuscripts required will be advertised through the BAD and BADBIR website. Investigators who have made a substantial contribution to the BADBIR registry will be encouraged to apply for involvement in developing research output and publication of data (see application form).

4. Key publications that report on research directly related to BADBIR, and detailed in the BADBIR research strategy (appendix 1, tbc) will be published with key named authors together with the banner of ‘the BADBIR Study Group’. An appendix detailing the role of each contributor will be included in any publication. This will include:
(i) people who have led directly on design, set up, recruitment of patients and running of BADBIR – BADBIR Steering Committee (see appendix 2)

(ii) people who have led on formulating the research question, data analysis and interpretation. This will vary depending on the research question

(iii) members of the data monitoring committee (if applicable)

Each of the authors listed in the role of BADBIR Study Group, in the order that is decided, so that they are appear on PubMed index (NB there may be a limitation on the number of authors that can appear; authors should check early with the target journal to clarify the listing arrangements and if numbers of authors exceed the limit, discuss with the Research Group).

5. Publications by investigators who make substantial use of BADBIR data in studies that do not form part of the BADBIR research portfolio (subject to the Terms of Reference for BADBIR) must cite the ‘BADBIR study group’. Authors within the BADBIR study group should be listed so as to appear as cited authors on PubMed. Authorship arrangements for such manuscripts should be discussed with the Steering Committee at an early stage to confirm that the work is outside the BADBIR research portfolio.

6. Suggestions for the order of authors in the named list:

(a) Put key “doers” in front
(b) Put key senior authors at the back
(c) Designated ‘banner authors’ (1st/2nd and 2nd last/last) will be determined for each of the specific research questions/ key publications
(d) First authorship and senior authorship may be shared between 1st/2nd and 2nd last/last, respectively
(e) In the author list, the 1st/2nd and 2nd last/last author positions should be agreed and if there is disagreement, this should be resolved by the Research Group.
(f) Banner authors would usually be from the Steering Committee, and that by definition, these individuals would form the Writing Group for any particular publication
(g) Have 2 Corresponding Authors
(h) Vary the order of authors from paper to paper to give all key people a chance of prominent authorship, and to reflect the strength of their contributions to particular papers
(i) The rest of the authors can be placed in the middle of the list in alphabetical order
(j) An example might be JN Smith*, BM Jones*, GP White, ER Brown†, J Morgan† and the BADBIR Study Group. * denotes joint 1st author, † joint senior author
7. Papers should be emailed to the Steering Committee at least 1 week prior to submission for comments on issues such as format, acknowledgements and scientific claims, but not to provide extensive peer review. A near-final version of manuscripts should be emailed to all named authors on the understanding that there will be a short turnaround time for comments as many of the papers will be under competitive pressure.

8. Abstracts are to be governed by similar guidelines on authorship and should also be sent to the Steering Committee at least 1 week before submission.

9. All abstracts, presentations and manuscripts produced using BADBIR data are required to be submitted to funding Pharma for preview for a period of 40 business days. All materials for preview must be provided as late draft versions with all results and graphics open to view. Decisions in relation to content and any revision to papers will remain the responsibility of the authors. To enable companies to protect their proprietary information if necessary, the submission of a publication may be delayed, at their request, for up to 30 calendar days. This period may be extended for an additional 60 calendar days in relation to patent applications.

10. Contributors Listed in Acknowledgments

All contributors who do not meet the criteria for authorship should be listed in an acknowledgments section.

Examples of those who might be acknowledged include:

(a) An investigator who has recruited patients to BADBIR but who has otherwise not contributed to the study design/analysis or interpretation. Such investigators should be listed, with contributing hospital and acknowledged as contributing to the acquisition of patient data for BADBIR.

(b) As detailed in (3), a mechanism of application is available for individuals with an academic/research interest who want to be involved in analyses and papers. Applications will be reviewed by the Research group who will then co-opt the individual onto the relevant Research Question Group as necessary.

(c) Other individuals to be listed only in the acknowledgements include those who have provided purely technical/management help, writing assistance, or a department chairperson who has provided only general support e.g. Marilyn Benham.

(d) The financial support of contributing pharmaceutical companies and the BAD should also be acknowledged.

Because readers may infer their endorsement of the data and conclusions, these persons must give written permission to be acknowledged.
Appendix 1 – BADBIR Publication Plan

Appendix 2 - listing of BADBIR Study Group

The BADBIR Study Group will include:

(i) BADBIR Steering Committee - to reviewed on a 2 year cycle Specific, additional responsibilities are stated.

Jonathan Barker  
David Burden - Chair, BADBIR Steering Committee  
Chris Griffiths - BADBIR Chief Investigator  
Sagair Hussain - BAD Biologics Manager  
Brian Kirby - Pharmaceutical liaison contact  
Linda Lawson  
Kathy McElhone - BADBIR Study Manager  
Ruth Murphy  
Anthony Ormerod - formerly Chair of BADBIR Steering Committee  
Caroline Owen  
Nick Reynolds - formerly Chair of BADBIR Research Committee  
Catherine Smith - formerly Chair of BADBIR Steering Committee  
Richard Warren

(ii) Data Monitoring Committee  
Robert Chalmers  
Carsten Flohr - Chair, Data Monitoring Committee  
David Prieto-Merino  
Karen Watson